An observational study in Multiple Sclerosis, sponsored by SYSNAV. Terminated at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by SYSNAV · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Multiple Sclerosis with a site in Egypt — 9 open to participants now, 12 under way, none of them phase 3. Multiple Sclerosis · Egypt.
Among the 51 studies in Multiple Sclerosis with a site in Egypt, this one is the 14th largest by enrollment of the 22 observational ones that give a count, is one of 5 that started in 2024, is one of 22 observational ones, and was the 34th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 51 studies in Multiple Sclerosis with a site in Egypt are open now. Recruiting first, the newest first:
Al Hayah University In Cairo · Sites in Egypt
Ages 20–40
Cairo University · Sites in Egypt
Ages 20–35
Benha University · Sites in Egypt
Ages 15–65
Cairo University · Sites in Egypt
Ages 20–45
Cairo University · Sites in Egypt
Ages 20–50
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is below the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 45 across the 29 interventional studies, 100 across the 22 observational. Of the 34 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 51 have an industry lead sponsor. The 10 most frequent:
SYSNAV is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
SYSNAV has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Multiple Sclerosis with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07937345Al Hayah University In CairoEccentric vs. Concentric Ankle Training in Multiple Sclerosis | 2027-01-18 |
| NCT07918339Cairo UniversityVirtual Reality Versus Mental Practice On Balance And Gait In Patients With Multiple Sclerosis | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies in Multiple Sclerosis with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis. The Syde® collected data will be compared to on-site conventional clinical endpoints for MS pathology (EDSS, FSS and T25FWT). Subjects with multiple sclerosis will be assessed every 6 months for 2 years.
Subjects followed for multiple sclerosis care at the investigational site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will wear the Syde® for 1 month every 6 months
Also known as: Syde®
Longitudinal change of 95th centile of stride velocity
change between baseline and Month 6, Month 12, Month 18 and Month 24
Time frame: 2 years
Correlation of the Syde® variables with the clinical assessments EDSS, FSS and T25FWT
Time frame: 2 years
Ran from Apr 2024 to primary completion in Apr 2025, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SYSNAV